CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07Submission of Matters to a Vote of Security Holders.
On April 27, 2018, Cellular Biomedicine Group, Inc. (the “Company”) completed its 2018 annual meeting of stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 17,003,968 shares. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 13,771,658 shares. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved, and Wen Tao (Steve) Liu, Nadir Patel and Bosun S. Hau were elected “Class III” directors.
The following is a tabulation of the voting on the proposals presented at the Annual Meeting:
(i) To elect three (3) “Class III” directors, each of whom will be elected for a term of three years, or until the election and qualification of their successors.
|
Nominee |
Shares Voted For |
Shares Withheld |
Broker Non-Vote |
|
Wen Tao (Steve) Liu |
10,467,304 |
99,156 |
0 |
|
Nadir Patel |
10,451,941 |
114,519 |
0 |
|
Bosun S. Hau |
10,343,972 |
222,488 |
0 |
(ii) To ratify the appointment of BDO China Shu Lun Pan Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
|
Shares Voted For |
Shares Voted Against |
Shares Abstaining |
Broker Non-Vote |
|
13,747,957 |
20,173 |
3,528 |
3,205,198 |
Item 7.01Regulation FD Disclosure.
On April 30, 2018, the Company issued a press release announcing the results of the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
99.1 Press Release, dated April 30, 2018
Cellular Biomedicine Group, Inc. ExhibitEX-99.1 2 cbmg_ex991.htm PRESS RELEASE Blueprint EXHIBIT 99.1 Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders SHANGHAI,…To view the full exhibit click here
About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
